Virological failure in HIV to triple therapy with dolutegravir-based firstline treatment: Rare but possible

24Citations
Citations of this article
58Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We describe a case of virological failure during initial treatment with tenofovir disoproxil fumarate/emtricitabine/dolutegravir twice daily, with concomitant rifampin treatment of staphylococcal infection, selection of R263K + E157Q, and low plasma dolutegravir levels. Using rifampin together with dolutegravir may require closer follow-up, and, if possible, plasma dolutegravir levels should be monitored.

Author supplied keywords

Cite

CITATION STYLE

APA

Pena, M. J., Chueca, N., D’Avolio, A., Zarzalejos, J. M., & Garcia, F. (2019, January 1). Virological failure in HIV to triple therapy with dolutegravir-based firstline treatment: Rare but possible. Open Forum Infectious Diseases. Oxford University Press. https://doi.org/10.1093/ofid/ofy332

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free